Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient Modified R-DHAP in R/R NHL
NCT03892421Phase 2Completed
- Sponsor
- La Raza Medical Center
- Start
- Apr 2018
- Primary completion
- Jan 2021
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, carboplatin, cytarabine and dexamethasone in non-Hodgkin lymphoma (NHL), sponsored by La Raza Medical Center. Primary endpoints: Overall Response Rate at 63 days and Incidence of hematological toxicities > grade 2 at 63 days. Started Apr 2018; status: completed.
02
Drugs
rituximabcarboplatincytarabinedexamethasone
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03892421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03892421.